Search results
Bristol Myers taps startup to boost cell therapy production
BioPharma Dive via Yahoo Finance· 5 days agoDive Brief: Bristol Myers Squibb is turning to a manufacturing startup to help produce cancer cell...
Calithera Biosciences (NASDAQ:CALA) Coverage Initiated by Analysts at StockNews.com
ETF DAILY NEWS· 4 days agoStockNews.com initiated coverage on shares of Calithera Biosciences (NASDAQ:CALA – Free Report) in a research note released on Monday morning. The brokerage issued a hold rating on the biotechnology ...
Bioengineered ‘mini-colons’ shed light on cancer progression
Nature· 3 days agoExperimental system to examine tumour formation over space and time.
Freenome to cut more than 100 employees in restructuring
MedTech Dive via Yahoo Finance· 2 days agoIntended to preserve resources, the layoffs come weeks after Freenome released study data on its...
3 Biotech Stocks to Buy on the Dip: April 2024
InvestorPlace· 24 hours agoIf you follow Warren Buffett’s advice of being greedy when others are fearful, then it probably makes sense to consider biotech stocks to buy on the dip....
PharmAbcine's U.S. Subsidiary, Wincal Biopharm, to Present Preclinical Data from its Proprietary OPC...
CBS 47 Fresno· 4 days agoBased in South San Francisco, California, WincalBio is an emerging biotech dedicated to developing next-generation ...
Cytokinetics executive sells over $680k in company stock By Investing.com
Investing.com· 1 day agoCytokinetics , Inc. (NASDAQ:CYTK) has reported a notable transaction by one of its top executives,...
Freenome to Lay off 20 Percent of Workforce
GenomeWeb News· 3 days agoThe South San Francisco, California-based firm said the layoffs are occurring across multiple company functions. " ...
Bristol Myers Squibb and Cellares Announce a $380M Worldwide Capacity Reservation and Supply...
Morningstar· 5 days agoBristol Myers Squibb and Cellares Announce a $380M Worldwide Capacity Reservation and Supply Agreement for the Manufacture of CAR T Cell Therapies to Bring the Promise of Cell Therapy to More ...
